Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28255498 | 0.89 | JAK2 (0.57) | JAK2KDM4EALDH1A1THRBHPGD | |
| SCHEMBL16826539 | 0.83 | KDM4E (0.61) | JAK2KDM4EALDH1A1HPGDKDR | |
| SCHEMBL16826531 | 0.81 | KIF11 (0.50) | JAK2KDM4EALDH1A1THRBHPGD | |
| SCHEMBL28082031 | 0.80 | KDM4E (0.65) | JAK2KDM4EALDH1A1THRBHPGD | |
| SCHEMBL16826538 | 0.80 | JAK2 (0.41) | JAK2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL30844878 | 0.76 | KDM4E (0.67) | KDM4EALDH1A1THRBHPGDKIF11 | |
| SCHEMBL69604 | 0.76 | KDM4E (0.67) | KDM4EALDH1A1THRBHPGDKIF11 | |
| SCHEMBL143977 | 0.76 | JAK2 (1.00) | JAK2KDM4EALDH1A1THRBHPGD | |
| SCHEMBL7926746 | 0.74 | KDM4E (0.71) | JAK2KDM4EALDH1A1THRBHPGD | |
| Hydrochloric Acid SCHEMBL9746959 | 0.74 | KDM4E (0.65) | KDM4EALDH1A1THRBHPGDKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-04 | — | — | US | disclosed |
| EP-3083603-B1 | BENZIMIDAZOLYL DERIVATIVES AS EP4 LIGANDS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-20160318905-A1 | Novel benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| EP-3083603-A1 | BENZIMIDAZOLE DERIVATIVES AS EP4-LIGANDS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-105814038-A | Benzimidazole derivatives as EP4 ligands | 拜耳医药股份公司 | 2016-07-27 | — | — | CN | disclosed |
| WO-2015091475-A1 | BENZIMIDAZOLE DERIVATIVES AS EP4-LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318905-A1 | Novel benzimidazole derivatives as EP4 ligands | PTGER4, PTGER1, EPB41 | JAK2 572/4885KDM4E 1542/4885ALDH1A1 511/4885 |
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | PTGER4, PTGER1, PTGER2 | JAK2 408/4885KDM4E 1547/4885ALDH1A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.